Related Experiment Video

Updated: May 17, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Simultaneous targeting of COX-2 and AKT using selenocoxib-1-GSH to inhibit melanoma

Raghavendra Gowda1, Subbarao V Madhunapantula, Dhimant Desai

  • 1Department of Pharmacology, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.

Molecular Cancer Therapeutics
|November 1, 2012
PubMed

Insights

A novel drug, selenocoxib-1-GSH, effectively targets COX-2 and PI3K/Akt pathways in melanoma cells. This new agent shows significant melanoma cell death and tumor reduction with minimal toxicity.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Melanoma is a deadly cancer with deregulated COX-2, PI3K/Akt, and MAPK signaling pathways.
  • Existing treatments lack agents targeting these multiple pathways simultaneously.
  • There is a need for novel therapeutic strategies against metastatic melanoma.

Purpose of the Study:

  • To synthesize and evaluate a novel agent, selenocoxib-1-GSH, targeting COX-2 and PI3K/Akt signaling pathways in melanoma.
  • To assess the efficacy and toxicity of selenocoxib-1-GSH in melanoma cells and xenograft models.
  • To investigate the mechanism of action of selenocoxib-1-GSH, including its effects on MAPK pathway activity.

Main Methods:

  • Synthesis of selenocoxib-1-GSH, a selenium-containing glutathione analogue of celecoxib.
  • In vitro evaluation of cytotoxicity against melanoma and normal cells, determining IC(50) values.
  • In vivo assessment of tumor growth inhibition in xenograft models and evaluation of toxicity.
  • Analysis of cellular proliferation and apoptosis following drug treatment.

Main Results:

  • Selenocoxib-1-GSH exhibited significantly higher potency against melanoma cells (IC(50) = 7.66 μmol/L) compared to celecoxib (IC(50) = 55.6 μmol/L).
  • The drug demonstrated a favorable therapeutic window, with IC(50) values for normal cells (36.3–41.2 μmol/L) much higher than for cancer cells.
  • Selenocoxib-1-GSH reduced xenografted tumor development by approximately 70% with negligible toxicity.
  • Treatment led to an ~80% decrease in cell proliferation and a ~200% increase in apoptosis in cultured cells.

Conclusions:

  • Selenocoxib-1-GSH is a potent, novel agent effective against melanoma by targeting COX-2 and PI3K/Akt signaling.
  • The drug exhibits significant anti-tumor activity and a favorable safety profile, warranting further investigation.
  • This study presents a promising new therapeutic strategy for treating metastatic melanoma.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...